Page 21 - Lantern Pharma News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Lantern Pharma to Participate in the Virtual 20th Annual Needham Healthcare Conference News provided by Share this article Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR ® artificial intelligence ("A.I.") platform to transform oncology drug discovery and development today announced that Panna Sharma, President and CEO of Lantern Pharma, will participate in the 20 th Annual Needham Healthcare Conference, to be held virtually on April 12-15, 2021. Mr. Sharma will participate in a fireside chat moderated by Needham & Company's Alexande...

Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR ® artificial intelligence ("A.I.") platform to transform oncology drug discovery and development, today announced a collaboration with Johns Hopkins Pediatric Oncology Division of The Sidney Kimmel Comprehensive Cancer Center and Dr. Eric Raabe, M.D., Ph.D. focused on Lantern's drug candidate LP-184 in the area of brain tumors, and specifically in Atypical Rhabdoid Tumors ("ATRT"), an ultra-rare and fast-growing cancerous tumor of the brain that presents primarily in children. "As w...

Share this article Share this article DALLAS, March 17, 2021 /PRNewswire/ -- Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR ® artificial intelligence ("A.I.") platform to transform oncology drug discovery and development today announced that it has filed seven patent applications globally on a novel DNA-damaging agent with anticancer properties. These patent applications include claims directed to a newly synthesized compound with promising in-vitro anticancer activity in a range of indications that are distinct from LP-184. This c...

/PRNewswire/ -- Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.")...

/PRNewswire/ -- Lantern Pharma (Nasdaq: LTRN), a clinical-stage biopharma company using its proprietary RADR® artificial intelligence ("A.I.") platform to...